Coinfection with hepatitis C virus and schistosomiasis: Fibrosis and treatment response
Author:
Open Access
- 1 January 2013
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 19 (17) , 2691-6
Abstract
To assess whether schistosomiasis coinfection with chronic hepatitis C virus (HCV) influences hepatic fibrosis and pegylated-interferon/ribavirin (PEG-IFN/RIB) therapy response. This study was designed as a retrospective analysis of 3596 chronic HCV patients enrolled in the Egyptian National Program for HCV treatment with PEG-IFN/RIB. All patients underwent liver biopsy and anti-schistosomal antibodies testing prior to HCV treatment. The serology results were used to categorize the patients into group A (positive schistosomal serology) or group B (negative schistosomal serology). Patients in group A were given oral antischistosomal treatment (praziquantel, single dose) at four weeks prior to PEG-IFN/RIB. All patients received a 48-wk course of PEG-IFN (PEG-IFNα2a or PEG-IFNα2b)/RIB therapy. Clinical and laboratory follow-up examinations were carried out for 24 wk after cessation of therapy (to week 72). Correlations of positive schistosomal serology with fibrosis and treatment response were assessed by multiple regression analysis. Schistosomal antibody was positive in 27.3% of patients (15.9% females and 84.1% males). The patients in group A were older (P = 0.008) and had a higher proportion of males (P = 0.002) than the patients in group B. There was no significant association between fibrosis stage and positive schistosomal serology (P = 0.703). Early virological response was achieved in significantly more patients in group B than in group A (89.4% vs 86.5%, P = 0.015). However, significantly more patients in group A experienced breakthrough at week 24 than patients in group B (36.3% vs 32.3%, P = 0.024). End of treatment response was achieved in more patients in group B than in group A (62.0% vs 59.1%) but the difference did not reach statistical significance (P = 0.108). Sustained virological response occurred in significantly more patients in group B than in group A (37.6% vs 27.7%, P = 0.000). Multivariate logistic regression analysis of patient data at treatment weeks 48 and 72 showed that positive schistosomal serology was associated with failure of response to treatment at week 48 (OR = 1.3, P = 0.02) and at week 72 (OR = 1.7, P < 0.01). Positive schistosomal serology has no effect on fibrosis staging but is significantly associated with failure of response to HCV treatment despite antischistosomal therapy.Keywords
This publication has 24 references indexed in Scilit:
- New Insight into the Antifibrotic Effects of Praziquantel on Mice in Infection with Schistosoma japonicumPLOS ONE, 2011
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Human schistosomiasisThe Lancet, 2006
- Progression of fibrosis in hepatitis C with and without schistosomiasisHepatology, 2006
- Schistosomal hepatic fibrosis and the interferon gamma receptor: a linkage analysis using single-nucleotide polymorphic markersEuropean Journal of Human Genetics, 2005
- Analysis of T cell responses against hepatitis C virus genotype 4 in EgyptJournal of Hepatology, 2004
- Repeated Exposure Induces Periportal Fibrosis in Schistosoma mansoni- Infected Baboons: Role of TGF-β and IL-4The Journal of Immunology, 2000
- The epidemiology of schistosomiasis in Egypt: summary findings in nine governorates.The American Journal of Tropical Medicine and Hygiene, 2000
- Evidence for a long-term effect of a single dose of praziquantel on Schistosoma mansoni-induced hepatosplenic lesions in northern Uganda.The American Journal of Tropical Medicine and Hygiene, 1999
- Reversal of Hepatic Fibrosis After Praziquantel Therapy of Murine SchistosomiasisThe American Journal of Tropical Medicine and Hygiene, 1985